Captopril in the treatment of heart failure;Captopril szivelegtelensegben

Acta Pharmaceutica Hungarica

Volumn 67, Issue 4, 1997, Pages 155-163

  Kékes, Ede ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VASODILATOR AGENT;

DRUG EFFICACY; HEART FAILURE; HEART INFARCTION; HEMODYNAMICS; HUMAN; SHORT SURVEY; CONGESTIVE HEART FAILURE; DRUG EFFECT; HEART; PATHOPHYSIOLOGY; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; HEART; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; VASODILATOR AGENTS;

EID: 0031179375     PISSN: 00016659     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (21)

1. Agostini, P. G. et al.: Afterload reduction a comparison of captopril and nifedipine in dilated cardiomyopathy. Brit. Heart. J. 55, 391-399 (1986).
2. Brown, J. J., Fraser, R., Lever, A. F., Robertson, J. S.: The renin-angiotensin system in congestive cardiac failure: a selective review. Eur. Heart J. 4, S/A, 85-87 (1983).
3. Burkart, F.: Rationale for current drug treatment. Eur. Heart J. 16, S/F 2-3 (1995).
4. Captopril Multicenter Research Group: A placebo controlled trial of captopril in refractory chronic congestive heart failure. JACC 2, 755-763 (1983).
5. Chinese Cardiac Study Collaborative Group: Oral captopril versus placebo among 13.634 pts with suspected myocardial infarction: interim report from the Chinese Cardiac Study. Lancet 345, 686-687 (1995).
6. Cohn, J. N. et al.: A comparison of enalapril with hydralazine isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Eng. J. Med. 325, 303-310 (1991).
7. Fouad, F. M. et al.: Captopril on congestive heart failre resistant to other vasodilatators. Eur. Heart J. 5, 47-54 (1984).
8. Harris, P.: The problem of defining heart failure. Cardiovasc. Drugs and Therapy 8, 447-452 (1994).
9. ISIS-4 Fourth International Study of Infarct Survival Collaborative Group ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and i.v. magnesium sulphate in 58.050 patients with suspected acute myocardial infarction. Lancet 345, 669-685 (1995).
10. Kékes E.: Captopril in heart failure. Acta Physiol. Hung. 77, 79-83 (1988).
11. Kékes E., Dékány M., Préda I.: Tartós orális vasodilatátor kezelés ischemiás szívbetegséghez társult szívelégtelenségben. Cardiol. Hung. 11, 139-153 (1982).
12. Kingma, J. H. et al.: Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Eur. Heart J. 15, 898-907 (1994).
13. Kleber, F. X., Niemöller, L., Doering, W.: Impact of converting enzyme inhibition on progression of chronic heart failure: results of Munich Mild Heart Failure Trial. Brit. Heart J. 67, 289-296 (1992).
14. Loh, E., Pfeffer, M. A.: Drug therapy to prevent congestive heart failure and left ventricular remodelling in "The pharmacologic management of heart disease" (Ed.: Kupersmith, J. and Deedwania, P. C.) Williams Wilkins, Baltimore, 1996. pp. 360-381.
15. Meerson, F. Z.: The myocardium in hyperfunction, hypertrophy and heart failure. Circ. Res. 25, S/2 1-163 (1969).
16. O'Neill, C. J. A. et al.: Effect of captopril on functional, physiological and biochemical outcome criteria in aged heart failure patients. Brit. J. Clin. Pharmacol. 33, 167-178 (1992).
17. Opie, L. H.: Angiotensin converting enzyme inhibitors. Whiley-Liss, New York, 1992.
18. Packer, M.: Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. Eur. Heart J. 26, S/F 4-7 (1995).
19. Pfeffer, M. A. et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N. Eng. J. Med. 327, 668-677 (1992).
20. The SOLD investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N. Eng. J. Med. 325, 293-302 (1991).
21. Walter, J. P.: Endothelial control of vascular and myocardial function in heart failure. Cardiovasc. Drugs and Therapy 8, 437-446 (1994).